Erytech Pharma (NASDAQ: ERYP) is one of 106 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its rivals? We will compare Erytech Pharma to related companies based on the strength of its earnings, risk, valuation, institutional ownership, analyst recommendations, profitability and dividends.
This is a summary of current ratings and price targets for Erytech Pharma and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Erytech Pharma Competitors||641||2219||5389||219||2.61|
Erytech Pharma presently has a consensus target price of $43.00, indicating a potential upside of 457.72%. As a group, “Biological products, except diagnostic” companies have a potential upside of 33.98%. Given Erytech Pharma’s stronger consensus rating and higher probable upside, research analysts clearly believe Erytech Pharma is more favorable than its rivals.
Earnings & Valuation
This table compares Erytech Pharma and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Erytech Pharma||N/A||-$37.89 million||-2.32|
|Erytech Pharma Competitors||$1.02 billion||$93.10 million||-4.69|
Erytech Pharma’s rivals have higher revenue and earnings than Erytech Pharma. Erytech Pharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Institutional & Insider Ownership
25.7% of Erytech Pharma shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 16.3% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Erytech Pharma and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Erytech Pharma Competitors||-8,316.86%||-75.40%||-24.08%|
Erytech Pharma beats its rivals on 7 of the 12 factors compared.
About Erytech Pharma
ERYTECH Pharma S.A., a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia. It is preparing for the launch of a pivotal Phase III clinical trial of eryaspase in the United States and Europe. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria and with Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. ERYTECH Pharma S.A. was founded in 2004 and is based in Lyon, France.
Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.